2024
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs J, Stanek C, Booth G, Symeonidis A, Shih A, Allen E, Gavriilaki E, Grossman B, Pavenski K, Moorehead A, Peyvandi F, Agosti P, Mancini I, Stephens L, Raval J, Mingot‐Castellano M, Crowe E, Daou L, Pai M, Arnold D, Marques M, Henrie R, Smith T, Sreenivasan G, Siniard R, Wallace L, Yamada C, Duque M, Wu Y, Harrington T, Byrnes D, Bitsani A, Davis A, Robinson D, Eichbaum Q, Villalba C, Juskewitch J, Kaiafa G, Kapsali E, Klapper E, Perez‐Alvarez I, Klein M, Kotsiou N, Lalayanni C, Mandala E, Aldarweesh F, Alkhateb R, Fortuny L, Mellios Z, Papalexandri A, Parsons M, Schlueter A, Tormey C, Wellard C, Wood E, Jia S, Wheeler A, Powers A, Webb C, Yates S, Bouzid R, Coppo P, Bloch E, Adkins B. The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes. American Journal Of Hematology 2024 PMID: 39136282, DOI: 10.1002/ajh.27458.Peer-Reviewed Original ResearchAddressing platelet insecurity – A national call to action
Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024 PMID: 39133194, DOI: 10.1111/trf.17987.Peer-Reviewed Original ResearchEfgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial
Jacobs J, Booth G, Stephens L, Tormey C, Adkins B. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. The Lancet 2024, 404: 433. PMID: 39097393, DOI: 10.1016/s0140-6736(24)01264-9.Peer-Reviewed Original ResearchTherapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Yurtsever N, Binns T, Hendrickson J, Tormey C, Lee E. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma. Lab Medicine 2024, lmae054. PMID: 39038224, DOI: 10.1093/labmed/lmae054.Peer-Reviewed Original ResearchA multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategiesFactitious disorder presenting as sickle cell disease: a case report
Jacobs J, Guarente J, Karp J, Grossman B, Ziman A, McGonigle A, Binns T, Gish T, Gorham J, Park Y, Perez-Alvarez I, Burner J, Mei Z, Ward D, Woo J, Booth G, Adkins B, Webb C, Yamada C, Lee G, Abels E, Marques M, Allen E, Fasano R, Crowe E, Tobian A, Tormey C, Bloch E. Factitious disorder presenting as sickle cell disease: a case report. The Lancet Regional Health - Americas 2024, 34: 100761. PMID: 38745885, PMCID: PMC11090869, DOI: 10.1016/j.lana.2024.100761.Peer-Reviewed Original ResearchSevere, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-dependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStay
2023
Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice?
Abels E, Adkins B, Cedeno K, Booth G, Allen E, Stephens L, Woo J, Tormey C, Jacobs J. Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice? Transfusion Medicine Reviews 2023, 38: 150810. PMID: 38194730, DOI: 10.1016/j.tmrv.2023.150810.Peer-Reviewed Original ResearchAntigen testingEvidence-based recommendationsFetal risksAlloimmunized pregnanciesPoor outcomeHemolytic diseasePractice guidelinesDecades-old practiceNarrative reviewTransfusion medicineUnnecessary riskRecent evidencePregnancyUnited StatesFetusesRiskCurrent United StatesValuable alternativeTesting algorithmObstetriciansCurrent landscapeDiseaseRecommendations
2022
Alloimmunization following antigen‐negative red blood cell transfusion
Jacobs J, Binns T, Abels E, Iyer K, Villalba C, Verma A, Sostin N, Tormey C. Alloimmunization following antigen‐negative red blood cell transfusion. Transfusion 2022, 63: 430-434. PMID: 36458330, DOI: 10.1111/trf.17208.Peer-Reviewed Case Reports and Technical NotesConceptsTransfusion of RBCsRed blood cell transfusionRed blood cell alloimmunizationPrevious antigen exposureBlood cell transfusionAlloantibody specificitiesCell transfusionRBC transfusionAntigen exposureRBC alloantibodiesAntigenic stimulusDetectable titersAntigenic stimulationMyeloid neoplasmsTransfusionAlloantibodiesAlloimmunizationParticular antigenPrior exposureStimulatory eventsExact mechanismCorresponding antibodiesRBCsExposurePregnancyEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2020
Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency
Gupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency. American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.Peer-Reviewed Original ResearchEndotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patientsThe evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2019
Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity
Baine I, Bahar B, Hendrickson JE, Hudson KE, Tormey CA. Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity. Transfusion 2019, 59: 1651-1656. PMID: 30811034, DOI: 10.1111/trf.15212.Peer-Reviewed Original ResearchTransfusion-related red blood cell alloantibodies: induction and consequences
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood 2019, 133: 1821-1830. PMID: 30808636, PMCID: PMC6484385, DOI: 10.1182/blood-2018-08-833962.Peer-Reviewed Original ResearchConceptsTransfusion recipientsBlood donorsPreventative strategiesBlood product exposureCompatible RBC unitsRBC alloantibody formationHemolytic transfusion reactionsDevelopment of alloantibodiesAdaptive immune factorsJudicious transfusionRBC alloimmunizationImmunomodulatory therapyAlloantibody formationBlood transfusionRBC alloantibodiesRecipient variablesFuture pregnanciesImmune factorsTransfusion reactionsBlood productsHemolytic diseaseFuture transfusionsHuman studiesTransfusionAlloantibodies
2018
Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia
Chandler JB, Siddon AJ, Bahel P, Torres R, Rinder HM, Tormey CA. Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia. Journal Of Clinical Pathology 2018, 72: 177. PMID: 30463936, DOI: 10.1136/jclinpath-2018-205438.Peer-Reviewed Original Research
2016
The Hidden Lesion.
Lee A, Tormey C. The Hidden Lesion. New England Journal Of Medicine 2016, 375: 1199. PMID: 27653584, DOI: 10.1056/nejmc1608553.Peer-Reviewed Original Research
2015
Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization
Ryder AB, Hendrickson JE, Tormey CA. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. British Journal Of Haematology 2015, 174: 483-485. PMID: 26456151, PMCID: PMC7025713, DOI: 10.1111/bjh.13781.Peer-Reviewed Original Research
2009
Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies
Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009, 114: 4279-4282. PMID: 19713462, DOI: 10.1182/blood-2009-06-227793.Peer-Reviewed Original Research